Meyka Pro banner
Sight Sciences, Inc.

Sight Sciences, Inc. Fundamental Analysis (NASDAQ: SGHT)

SGHT●NASDAQ
HealthcareMedical - Devices
$11.21
$0.46(4.28%)
U.S. Market is Open · 13:10

Sight Sciences, Inc. Fundamental Analysis (NASDAQ: SGHT)

Sight Sciences, Inc. (NASDAQ: SGHT) shows weak financial fundamentals with a PE ratio of -20.75, profit margin of -32.13%, and ROE of -51.66%. The company generates $0.1B in annual revenue with weak year-over-year growth of -3.13%.

Key Strengths

Cash Position12.86%
PEG Ratio-0.35
Current Ratio5.04

Areas of Concern

ROE-51.66%
Operating Margin-29.52%
We analyze SGHT's fundamental strength across five key dimensions.

The stock receives a Fundamental Health Score of -57.9/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.

Fundamental Health Score

F
-57.9/100

We analyze SGHT's fundamental strength across five key dimensions:

Efficiency Score

Weak

SGHT struggles to generate sufficient returns from assets.

ROA > 10%
-27.06%

Valuation Score

Excellent

SGHT trades at attractive valuation levels.

PE < 25
-20.75
PEG Ratio < 2
-0.35

Growth Score

Moderate

SGHT shows steady but slowing expansion.

Revenue Growth > 5%
-3.13%
EPS Growth > 10%
28.16%

Financial Health Score

Excellent

SGHT maintains a strong and stable balance sheet.

Debt/Equity < 1
0.86
Current Ratio > 1
5.04

Profitability Score

Weak

SGHT struggles to sustain strong margins.

ROE > 15%
-5166.18%
Net Margin ≥ 15%
-32.13%
Positive Free Cash Flow
No

Key Financial Metrics

Is SGHT Expensive or Cheap?

P/E Ratio

SGHT trades at -20.75 times earnings. This suggests potential undervaluation.

-20.75

PEG Ratio

When adjusting for growth, SGHT's PEG of -0.35 indicates potential undervaluation.

-0.35

Price to Book

The market values Sight Sciences, Inc. at 12.07 times its book value. This suggests the stock is fully valued or overvalued on an asset basis.

12.07

EV/EBITDA

Enterprise value stands at -25.95 times EBITDA. This is generally considered low.

-25.95

How Well Does SGHT Make Money?

Net Profit Margin

For every $100 in sales, Sight Sciences, Inc. keeps $-32.13 as profit after all expenses.

-32.13%

Operating Margin

Core operations generate -29.52 in profit for every $100 in revenue, before interest and taxes.

-29.52%

ROE

Management delivers $-51.66 in profit for every $100 of shareholder equity.

-51.66%

ROA

Sight Sciences, Inc. generates $-27.06 in profit for every $100 in assets, demonstrating efficient asset deployment.

-27.06%

Following the Money - Real Cash Generation

Operating Cash Flow

Sight Sciences, Inc. generates limited operating cash flow of $-17.06M, signaling weaker underlying cash strength.

$-17.06M

Free Cash Flow

Sight Sciences, Inc. generates weak or negative free cash flow of $-17.05M, restricting financial flexibility.

$-17.05M

FCF Per Share

Each share generates $-0.31 in free cash annually.

$-0.31

FCF Yield

SGHT converts -2.80% of its market value into free cash.

-2.80%

Financial Ratios Analysis

Valuation Ratios

P/E Ratio

Price to earnings ratio

-20.75

vs 25 benchmark

PEG Ratio

Price/earnings to growth ratio

-0.35

vs 25 benchmark

P/B Ratio

Price to book value ratio

12.07

vs 25 benchmark

P/S Ratio

Price to sales ratio

6.76

vs 25 benchmark

Financial Health

Debt/Equity

Total debt to shareholders' equity

0.86

vs 25 benchmark

Current Ratio

Current assets to current liabilities

5.04

vs 25 benchmark

Efficiency Ratios

ROE

Return on equity percentage

-0.52

vs 25 benchmark

ROA

Return on assets percentage

-0.27

vs 25 benchmark

ROCE

Return on capital employed

-0.31

vs 25 benchmark

How SGHT Stacks Against Its Sector Peers

MetricSGHT ValueSector AveragePerformance
P/E Ratio-20.7531.66 Better (Cheaper)
ROE-51.66%501.00% Weak
Net Margin-32.13%-3647.00% (disorted) Weak
Debt/Equity0.86-0.30 (disorted) Distorted
Current Ratio5.045.78 Strong Liquidity
ROA-27.06%-262.00% (disorted) Weak

SGHT outperforms its industry in 2 out of 6 key metrics, but lagging in ROE.

Historical Growth Performance

5-Year Growth Trajectory

This section reviews Sight Sciences, Inc.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.

Revenue CAGR

151.01%

Industry Style: Defensive, Growth, Innovation

High Growth

EPS CAGR

0.67%

Industry Style: Defensive, Growth, Innovation

Growing

FCF CAGR

17.23%

Industry Style: Defensive, Growth, Innovation

High Growth

Fundamental Analysis FAQ